Hyperlipidemia Abnormal obesity Smoking HT Diabetes Stress Number of treatments Risk benefits Renal artery denervation Benefit triglycerides & HDL slight No No YES Reduces Insulin resistance Unknown 1 Risk of vascular damage- no further treatment Drug treatments Yes No mortality for ↓ triglycerides Maybe Maybe YES with mortality data No primary endpoint CV mortality data Maybe in patients after MI 6 different drugs Lifelong therapy HT: Hypertension HDL: High Density Lipoprotein Adapted from INTERHEART; CV: Cardiovascular Juni P, et al. Lancet 2004; 364: MI: Myocardial Infarction 2021-9 Comparing important cardiovascular risk factor treatment options, reveals the potential of renal artery denervation as one treatment that may have many benefits in reducing cardio-metabolic risk. However, risk to patient with renal artery denervation must be further evaluated with large trials for safety and long term concerns

Table 1: Strategies for cardiovascular global risk reduction.